Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Status:
Completed
Trial end date:
2019-03-06
Target enrollment:
Participant gender:
Summary
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled
diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of
the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences
frequently lead to below-knee amputation of the affected limb.
Currently treatment options are limited, and no pharmaceutical treatment has been efficacious
in the medical literature. The purpose of this pilot study is to investigate the potential of
the medication denosumab for acute stage Charcot neuroarthropathy.